A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens

Kade D. Roberts, Yan Zhu, Mohammad A.K. Azad, Mei Ling Han, Jiping Wang, Lynn Wang, Heidi H. Yu, Andrew S. Horne, Jo Anne Pinson, David Rudd, Nicolas H. Voelcker, Nitin A. Patil, Jinxin Zhao, Xukai Jiang, Jing Lu, Ke Chen, Olga Lomovskaya, Scott J. Hecker, Philip E. Thompson, Roger L. NationMichael N. Dudley, David C. Griffith, Tony Velkov, Jian Li

Research output: Contribution to journalArticleResearchpeer-review

36 Citations (Scopus)


The emergence of multidrug-resistant (MDR) Gram-negative pathogens is an urgent global medical challenge. The old polymyxin lipopeptide antibiotics (polymyxin B and colistin) are often the only therapeutic option due to resistance to all other classes of antibiotics and the lean antibiotic drug development pipeline. However, polymyxin B and colistin suffer from major issues in safety (dose-limiting nephrotoxicity, acute toxicity), pharmacokinetics (poor exposure in the lungs) and efficacy (negligible activity against pulmonary infections) that have severely limited their clinical utility. Here we employ chemical biology to systematically optimize multiple non-conserved positions in the polymyxin scaffold, and successfully disconnect the therapeutic efficacy from the toxicity to develop a new synthetic lipopeptide, structurally and pharmacologically distinct from polymyxin B and colistin. This resulted in the clinical candidate F365 (QPX9003) with superior safety and efficacy against lung infections caused by top-priority MDR pathogens Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae.

Original languageEnglish
Article number1625
Number of pages15
JournalNature Communications
Issue number1
Publication statusPublished - 2022

Cite this